Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements study found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://businessbookmark.com/story6355338/not-known-factual-statements-about-conolidin-to-replace-traditional-painkillers